Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06341621 | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib(Rainbow) | recruiting | Phase 3 | 1,900 | Fudan UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06345365 | MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 154 | Zhongnan HospitalOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06350825 | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06338683 | Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer | recruiting | Phase 3 | 230 | Qinghai Red Cross HospitalOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06330337 | Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma | recruiting | Phase 3 | 58 | The Third Affiliated hospital of Zhejiang Chinese Medical UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | recruiting | Phase 3 | 686 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases(ALADDIN) | recruiting | Phase 3 | 152 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05085028 | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(REFINE-Lung) | recruiting | Phase 3 | 1,750 | Imperial College LondonOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04597294 | Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence(CHIMERA) | recruiting | Phase 3 | 600 | Jagiellonian UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT01935778 | Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH | recruiting | Phase 3 | 286 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04642027 | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy(PERYTON) | recruiting | Phase 3 | 538 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06268652 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | recruiting | Phase 3 | 302 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06247605 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | recruiting | Phase 3 | 243 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | recruiting | Phase 3 | 372 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | recruiting | Phase 3 | 472 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT05918094 | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06208917 | Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children | recruiting | Phase 3 | 376 | Yizhuo ZhangOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | recruiting | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | recruiting | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06177015 | Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | recruiting | Phase 3 | 452 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06017284 | Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer(PTCA199-5) | recruiting | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05781217 | Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624(URONCOR 06-24) | recruiting | Phase 3 | 534 | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134388 | Sulfasalazine in Patients With Metastatic Colorectal Cancer | recruiting | Phase 3 | 50 | Tanta UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | recruiting | Phase 3 | 1,199 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06071897 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | recruiting | Phase 3 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03216525 | Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol | recruiting | Phase 3 | 136 | Brigham and Women's HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | recruiting | Phase 3 | 570 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06043973 | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance | recruiting | Phase 3 | 98 | Qianfoshan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04989647 | Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy(CERVANTES) | recruiting | Phase 3 | 514 | The Central and Eastern European Gynecologic Oncology GroupOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05264896 | Perioperative FLOT vs Adjuvant XELOX for CA Stomach | recruiting | Phase 3 | 110 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2024source: clinicaltrials